



Docket No.: 65792(46342)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Eiji Sunahara et al.

Application No.: 10/584,183

Confirmation No.: 1851

Filed: January 3, 2007

Art Unit: 1653

For: PREVENTIVE/REMEDY FOR CANCER

Examiner: Not Yet Assigned

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is further Applicants' Information Disclosure Statement filed on February 6, 2008. Applicants note that this Supplemental IDS is being filed to correct a typographical error in the citation of reference CE PTO/SB/08 – in particular, Applicants have corrected "Pho-specific" to properly read "Rho-specific".

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)). The references were first cited in a Supplementary European Search Report dated December 3, 2007 for the corresponding European application no. EP 04 80 8074, a copy of which is enclosed herewith.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

It is believed that no fees are required in connection with this submission. However, the Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 65792(46342).

Dated: February 26, 2008

Respectfully submitted,  
By  
Lisa Świścz Hazzard  
Registration No.: 44,368  
EDWARDS ANGELL PALMER & DODGE  
LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 517-5512  
Attorneys/Agents For Applicant